Claims for Patent: 7,625,939

Summary for Patent: 7,625,939

Title:	Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors
Abstract:	The present invention relates to DP IV-inhibitors of formula (1) ##STR00001## for the treatment and/or prophylaxis of diseases of mammals including cancer and tumors, metastasis and tumor colonization; and metabolic diseases.
Inventor(s):	Heiser; Ulrich (Halle/Saale, DE), Niestroj; Andre J. (Sennewitz, DE), Gaertner; Ulf-Torsten (Halle/Saale, DE), Demuth; Hans-Ulrich (Halle/Saale, DE)
Assignee:	Probiodrug AG (Halle/Saale, DE)
Application Number:	12/120,595
Patent Claims:	1. A compound of formula (I): ##STR00015## wherein R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, heterocyclyl, carbocyclyl, aryl, -alkylaryl, heteroaryl-alkylheteroaryl and an amino acid or a peptide residue; R.sup.3 represents hydrogen; Z is a group of formula I or II: ##STR00016## wherein X.sup.1 and X.sup.2 independently represent OR.sup.4; R.sup.4 is selected from the group consisting of hydrogen; alkyl, alkenyl, alkynyl, cycloalkyl any of which aforementioned four groups may optionally be substituted by hydroxy; heterocyclyl, carbocyclyl, aryl, -alkylaryl, heteroaryl and -alkylheteroaryl; Y.sup.1 and Y.sup.2 are independently selected from hydroxy, alkoxy, cycloalkyloxy, aryloxy and heteroaryloxy; or Y.sup.1 and Y.sup.2 are connected to form one of the following cyclic boronic diester groups: ##STR00017## wherein R.sup.9-R.sup.18 are independently hydrogen, alkyl, cycloalkyl or aryl; and each R.sup.19 group is independently selected from hydrogen, alkyl, aryl, halo, alkoxy, aryloxy, thioalkyl and thioaryl; when Z represents a group of formula (I): ##STR00018## then R.sup.3 may also represent alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, heterocyclyl, carbocyclyl, aryl, -alkylaryl, -alkylheteroaryl, an amino acid or a peptide residue; and when Z represents a group of formula (I) R.sup.1 and R.sup.3 may also optionally be connected to form a ring of the structure of formula (III) ##STR00019## wherein m is an integer in the range of 2 to 6; R.sup.2 is as defined above; and R.sup.5 and R.sup.6 are independently selected from hydrogen, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, halo, amino, substituted amino, carbocyclyl, aryl, arylalkyl-, heteroaryl, heteroarylalkyl-, heterocyclyl, alkylcarbonylamino-, arylcarbonylamino-, alkoxycarbonylamino-, aryloxycarbonylamino-, alkoxycarbonyl-, aryloxycarbonyl-, and alkylaminocarbonylamino-; including all stereoisomers and pharmaceutically acceptable salts thereof. 2. A compound according to claim 1, wherein Z is a group of formula (I). 3. A compound according to claim 1, wherein R.sup.4 represents hydrogen, lower alkyl or a substituted phenyl ring. 4. A compound according to any one of claims 1 to 3, wherein R.sup.1, R.sup.2 and R.sup.3 independently represent hydrogen, alkyl, alkylcycloalkyl or cycloalkyl. 5. A compound according to claim 1 wherein Z is a group of formula (II). 6. A compound according to claim 1, wherein Y.sup.1 and Y.sup.2 represent OH. 7. A compound of any one of claims 1, wherein R.sup.2 is hydrogen. 8. A compound of any one of claims 1, wherein R.sup.1 represents C.sub.2-C.sub.6 alkyl. 9. A compound according to claim 8, wherein R.sup.1 represents CMe.sub.3, CHMe.sub.2 or CHMeCH.sub.2Me. 10. A compound according to claim 9, wherein the moiety HR.sup.3N--CR.sup.1R.sup.2--CO-- represents the residue of L-valine, L-isoleucine or L-(t-butyl)glycine. 11. A compound according to claim 1, wherein R.sup.1, R.sup.2, R.sup.3, and Z are defined in the following table, TABLE-US-00003 Example R.sup.1 * R.sup.2 R.sup.3 Z 1 L-CHMe.sub.2 H H B(OH).sub.2 2 L-CMe H H B(OH).sub.2 3 L-CHMeCH.sub.2Me H H B(OH).sub.2 * L indicates that the amino acid moiety has L stereochemistry or a pharmaceutically acceptable salt thereof. 12. A pharmaceutical composition comprising at least one compound according to claim 1 optionally in combination with at least one therapeutically acceptable carrier and/or excipient. 13. The pharmaceutical composition according to claim 12 for parenteral, enteral or oral administration. 14. The pharmaceutical composition of claim 12, which comprises additionally at least one anti-tumor drug selected from the group consisting of cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimitotic agents, procarbazine, hydroxyurea, asparaginase, corticosteroids, mytotane (O,P1-(DDD)), interferons and radioactive agents. 15. The pharmaceutical composition of claim 12, which comprises additionally at least one anti-diabetic agent. 16. The pharmaceutical composition of claim 12, which comprises additionally at least one agent selected from the group consisting of (a) other DP IV inhibitors (b) insulin sensitizers selected from the group consisting of (i) PPAR agonists, (ii) biguanides, and (iii) protein tyrosin phosphatase-1B (PTP-1B) inhibitors; (c) insulin and insulin mimetics; (d) sulfonylureas and other insulin secretagogues; (e) .alpha.-glucosidase inhibitors; (f) glucagon receptor agonists; (g) GLP-1; GLP-1 mimetics, e.g. N,N-2211 (liraglutide), and GLP-1 receptor agonists; (h) GLP-2; GLP-2 mimetics, e.g. ALX-0600 (teduglutide) and GLP-2 receptor agonists; (i) exendin-4 and exendin-4 mimetics, e.g. exenatide (AC-2993, synthetic exendin-4); (j) GIP, GIP mimetics, and GIP receptor agonists; (k) PACAP, PACAP mimetics, and PACAP receptor 3 agonists; (l) cholesterol lowering agents selected from the group consisting of (i) HMG-CoA reductase inhibitors, (ii) sequestrants, (iii) nicotinyl alcohol, nicotinic acid and salts thereof, (iv) PPAR.alpha. agonists, (v) PPAR.alpha./.gamma. dual agonists, (vi) inhibitors of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitors, and (viii) antioxidants; (m) PPAR.delta. agonists; (n) antiobesity compounds; (o) an ileal bile acid transporter inhibitor; and (p) anti-inflammatory agents. 17. The pharmaceutical composition of claim 12, which further comprises a gene therapeutic expression system for GLP-1 comprising at least one of: (i) a viral vector comprising (a) a polynucleotide sequence encoding GLP-1 (glucagon like peptide-1); (b) a polynucleotide sequence encoding a signal sequence upstream of (a); (c) a polyadenylation signal downstream of (a); and (d) a polynucleotide sequence encoding a proteolytic cleavage site located between the polynucleotide sequence encoding GLP-1 and the polynucleotide sequence encoding the signal sequence; wherein the expression of GLP-1 underlies a constitutive promoter or is controlled by a regulatable promoter; optionally, the viral vector comprises a polynucleotide sequence encoding GIP (glucose dependent insulinotropic peptide); optionally, the viral vector is encompassed by a mammalian cell; and (ii) a gene therapeutic expression system for GIP comprising a viral vector comprising (a) a polynucleotide sequence encoding GIP (glucose dependent insulinotropic peptide); (b) a polynucleotide sequence encoding a signal sequence upstream of (a); (c) a polyadenylation signal downstream of (a); and (d) a polynucleotide sequence encoding a proteolytic cleavage site located between the polynucleotide sequence encoding GIP and the polynucleotide sequence encoding the signal sequence; wherein the expression of GIP underlies a constitutive promoter or is controlled by a regulatable promoter; optionally, the viral vector comprises a polynucleotide sequence encoding GLP-1 (glucagon like peptide 1); and optionally, the viral vector is encompassed by a mammalian cell. 18. The pharmaceutical composition of claim 17, wherein at least one of the following conditions are satisfied: the signal sequence upstream of the gene of interest (GLP-1; GIP) is the murine immunoglobulin .kappa. signal sequence or the glia monster exendin signal sequence; the polyadenylation signal downstream of the gene of interest (GLP-1; GIP) is derived from simian virus 40 (SV 40); the proteolytic cleavage site is cleaved by furin protease; the gene delivery vector for expression the gene of interest is an adenoviral, retroviral, leniviral, adeno associated viral vector; and the constitutive promoter is a cytomegalovirus (CMV) promoter, or a Rous sarcoma long-terminal repeat (LTR) sequence, and the SV 40 early gene gene promoter; and the inducible promoter comprises a tetracycline-resistance operon.

Details for Patent 7,625,939

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-11-14